Skip to main content

Fiona Blackhall MD, PhD

Fiona Blackhall MD, PhD, FRCP, is a Professor of Thoracic Oncology with expertise in personalized medicine and circulating biomarkers within the Institute of Cancer Studies, University of Manchester and has been a Consultant Medical Oncologist at The Christie Hospital, Manchester since 2005. She has conducted over 50 therapeutic clinical trials, including practice-changing precision medicine studies, and led on new directions in radiotherapy-related research and supportive palliative care research.

In the UK she has served on the National Cancer Research Institute (NCRI) lung cancer group and the British Thoracic Oncology Group Steering Committee. In Europe she has served as co-chair of the translational subgroup of the European Thoracic Oncology Platform and on the scientific committee for the European Society of Medical Oncology (ESMO) and on the ESMO consensus guidelines panel for lung cancer. She has been a faculty member and invited speaker for the American Society of Medical Oncology Annual Meeting and for the International Association for the Study of Lung Cancer. She has >130 peer-reviewed publications and has regularly presented abstracts and invited talks at international congresses.

Fiona conducts clinical trials of new drugs for the treatment of lung cancer and translational research in clinically relevant biomarkers. This includes circulating tumor cells and circulating tumor DNA that can be used to predict response to treatment and understand biology that can be exploited for therapeutic control. She is Clinical Trials Theme Lead for the recently established Cancer Research UK Lung Cancer Centre of Excellence (2014), which is a recognised research partnership between The University of Manchester and University College London. Her overall aim is to contribute clinically relevant lung cancer research to improve outcomes for lung cancer patients and ultimately to make lung cancer a less common and less deadly disease.

Latest contributions from Fiona Blackhall

17-05-2019 | Small-cell lung cancer | Highlight | News

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

04-01-2018 | Small-cell lung cancer | Conference report | Article

Progress in small cell lung cancer: an update from the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan

Advisory Board member Fiona Blackhall discusses the major new results in small cell lung cancer presented at the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan.

17-10-2017 | Fiona Blackhall | Article

Advisory board comment

Comment on: No survival, QoL gain for many EMA cancer drug approvals

26-07-2017 | Non-small cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

Image Credits